Key Takeaways Gilead will acquire Ouro Medicines for $1.675B upfront plus $500M in milestones, boosting its pipeline.GILD gains OM336, a bispecific T-cell engager showing early promise in autoimmune diseases like AIHA and ITP.GILD is exploring a partnership with Galapagos to co-develop OM336 and share development costs and royalties.Gilead Sciences (GILD) has agreed to acquire privately held biotechnology company Ouro Medicines, strengthening its push into innovative therapies for autoimmune diseases.The de ...

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness –CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseasesAppointed industry veteran Lucinda Warren as Chief Financial and Business OfficerRaised net proceeds of $10.2M through an underwritten public offeringAnnounced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Entitled to receive upfront payments tot ...

Core Insights - Iovance Biotherapeutics Inc. is recognized as a promising investment opportunity by hedge funds due to its innovative lifileucel TIL cell therapy showing positive early clinical trial results for advanced soft tissue sarcomas [1][7] Group 1: Clinical Trial Results - The pilot clinical trial for lifileucel TIL therapy reported a 50% objective response rate among the first six evaluable patients, with deep responses improving over time despite a high baseline disease burden [2][3] - The therapy addresses a significant unmet medical need for aggressive cancers, affecting over 8,000 patients annually in the US and Europe, where current second-line treatments yield response rates of less than 5% [2] Group 2: Safety and Future Plans - Medical experts noted that the one-time immunotherapy treatment showed unprecedented results for refractory patients who had limited success with chemotherapy [3] - Iovance plans to initiate a single-arm registrational trial for second-line advanced UPS and DDLPS in Q2 2026 following the positive trial results [3] Group 3: Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies using autologous tumor-infiltrating lymphocytes for metastatic melanoma and other solid tumors [4]

Summary of Gilead's Conference Call Company Overview - **Company**: Gilead Sciences - **Industry**: Biotechnology and Pharmaceuticals Key Points HIV Treatment and Prevention - Gilead is focusing on two major areas in HIV: treatment and prevention [4] - The company has prioritized long-acting therapies, moving from daily oral medications to options that can be administered every six months [5] - Two main approaches for long-acting treatment include: - Combination of lenacapavir and broadly neutralizing antibodies (bNabs) administered every six months [6] - An injectable option combining lenacapavir with integrase inhibitor GS-3242, targeting administration every 4 to 6 months [7][8] - Approximately 40% of HIV patients in the U.S. are either undiagnosed or not virologically suppressed, indicating a significant market opportunity [9] - Gilead is developing a 12-month pre-exposure prophylaxis (PrEP) option, with a smaller study expected to yield results in 2027 and potential patient access by 2028 [12][13] Livdelzi and Phase 3 IDEAL Study - Livdelzi has shown strong efficacy in primary biliary cholangitis (PBC) patients, particularly in those classified as inadequate responders [15] - The ongoing Phase 3 IDEAL study aims to expand the treated population by including incomplete responders, potentially doubling the addressable market [16] Business Development and Acquisitions - Gilead's acquisition of Arcellx is seen as financially attractive and expected to be accretive to EPS by 2028 [21] - The acquisition is based on a favorable view of peak sales opportunities for anito-cel, a BCMA cell therapy for multiple myeloma, with expected approvals in the near term [22][23] - Gilead is committed to a dual strategy of partnerships and direct acquisitions to drive innovation and shareholder value [30][32] In Vivo CAR T and Cell Therapy - Gilead is investing in in vivo CAR T therapies, which could revolutionize the delivery and cost of CAR T treatments [35][38] - The company aims to integrate in vivo CAR T into its existing cell therapy portfolio, expanding into new indications such as multiple myeloma [44] Trodelvy in Oncology - Trodelvy is positioned as a standard of care in triple-negative breast cancer (TNBC), with ongoing pivotal trials to support its use in first-line settings [48][50] - Gilead is exploring additional combinations and tumor types for Trodelvy, enhancing its competitive position in the market [49] Early-Stage Pipeline in Inflammation and Oncology - Gilead has several early-stage programs in inflammation, including an oral TPL2 inhibitor and IRAK4 inhibitors, with data expected later this year [52][53] - The company is also exploring novel immuno-oncology approaches, including a CCR8 antibody targeting regulatory T cells, which shows promise for monotherapy activity [60] Additional Insights - Gilead's strategic focus on long-acting therapies in HIV and expanding its oncology portfolio reflects a commitment to addressing unmet medical needs and capturing market opportunities [5][15][48] - The company's approach to acquisitions and partnerships indicates a proactive stance in enhancing its product pipeline and market presence [21][30]

Summary of Nkarta's Conference Call Company Overview - **Company**: Nkarta - **Focus**: Development of AlloCAR NK program and NKX019 targeting autoimmune diseases Key Points Transition and Strategy - Nkarta has undergone a significant transformation, focusing on the AlloCAR NK program and NKX019, shifting from an oncology-centric approach to a concentrated effort on autoimmune diseases [3][5][10] - The company has streamlined its focus to one target with six initial indications, emphasizing the importance of having sufficient capital to support data generation without the need for immediate fundraising [10][11] Clinical Development and Team Changes - The team has transitioned from oncology specialists to experts in immunology and autoimmune diseases, including hiring a new Chief Medical Officer (CMO) with rheumatology experience [15][17] - The manufacturing process has been optimized by having lab personnel directly manage and execute tasks, enhancing efficiency [18][19] NK Cell Advantages - NK cells are positioned as advantageous for outpatient settings due to their safety profile, with no observed cytokine release syndrome (CRS) or neurotoxicity in autoimmune trials [26][27] - The combination of NK cells with lymphodepletion (using fludarabine and cyclophosphamide) is believed to enhance B-cell depletion, which is crucial for achieving durable clinical remissions [29][30] Clinical Trials and Data Expectations - Nkarta is currently in the process of dose escalation, aiming for a regimen of 4 billion cells administered three times, with the goal of demonstrating best responses in upcoming clinical updates [46][47] - The company anticipates that the data will support the efficacy and safety of their NK cell therapy, with a focus on identifying the most promising indications for further development [52][58] Regulatory Environment - Nkarta has established a positive relationship with the FDA, with consistent communication and protocol amendments, which is crucial for navigating the regulatory landscape [76][77] - The company is optimistic about leveraging safety data from oncology trials to support their autoimmune indications [71][75] Patient Engagement and Enrollment - Nkarta has improved patient enrollment by addressing bottlenecks and enhancing communication with patient advocacy groups, making patients more aware of the potential benefits of cell therapies [92][95] - The company is committed to supporting patients throughout their clinical trial journey, including providing fertility preservation options and logistical assistance [101][103] Future Outlook - Nkarta's cash runway extends into 2029, allowing for the advancement of pivotal trials without immediate financial pressure [59][62] - The company is focused on narrowing down indications based on clinical data and patient enrollment trends, aiming for timely milestones in their development pipeline [54][56] Unique Positioning - Nkarta believes that their NK cell therapy could bridge the gap between community settings and specialized centers, offering a flexible treatment option for patients with autoimmune diseases [32][34] - The potential for long-term drug-free remissions with NK cell therapy is seen as a transformative opportunity for patients, particularly younger individuals seeking alternatives to chronic immunosuppressive treatments [36][37] Additional Insights - The rheumatology field is becoming increasingly competitive, with more clinical trials and interest from investors, which could benefit Nkarta as they navigate their development strategy [84][86] - The company is exploring various autoimmune indications, including systemic lupus erythematosus (SLE), with promising early data suggesting the efficacy of NK cells in these settings [87][88] This summary encapsulates the key discussions and insights from Nkarta's conference call, highlighting the company's strategic focus, clinical development plans, and the potential advantages of their NK cell therapies in treating autoimmune diseases.

Core Viewpoint - Kyverna Therapeutics has appointed Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors, enhancing its leadership team as the company advances towards commercialization of its cell therapies for autoimmune diseases [1][3]. Group 1: Board Appointments - Sravan K. Emany will serve as the Audit Committee Chair, succeeding Dan Spiegelman, who has stepped down from the Board [2]. - Andrew Miller, Ph.D. is recognized for his extensive experience in clinical development and product approval, which will support Kyverna's growth [1][3]. Group 2: Leadership Experience - Sravan Emany has a strong background in financial leadership, currently serving as CFO of Beam Therapeutics, and has held significant roles in investment banking, including at Bank of America and Goldman Sachs [3][4]. - Dr. Andrew Miller was the Founder and President of R&D at Karuna Therapeutics, which was acquired by Bristol Myers Squibb for $14 billion in 2024, and has been recognized as one of Time Magazine's 100 Next Generation Leaders [4]. Group 3: Company Overview - Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, with its lead candidate, miv-cel, showing potential to change treatment paradigms for B-cell-driven autoimmune diseases [5]. - The company is advancing its neuroimmunology franchise with completed and ongoing registrational trials for conditions such as stiff person syndrome and generalized myasthenia gravis [5].

Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific Enables scalable, automated manufacturing of diverse immune cell therapies using proprietary 3D expansion technology Strengthens positioning in China’s growing cell therapy market and supports cross-border partnerships HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq and TASE: PLUR ), a leading biotechnology company leveraging its ...

Core Insights - Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, which focuses on engineering immune cells in vivo, potentially enhancing genetic medicine and cell engineering innovation [1][3] Company Overview - Eli Lilly is a long-established pharmaceutical company that has been making significant contributions to healthcare for nearly 150 years, focusing on various therapeutic areas including diabetes, obesity, Alzheimer's disease, immune system disorders, and cancer [5] - Orna Therapeutics specializes in developing a new class of therapeutics using engineered circular RNA and lipid nanoparticles, aiming to enable the body to generate its own cell therapies for treating diseases [2][6] Acquisition Details - The acquisition deal includes a total potential payment of up to $2.4 billion to Orna's shareholders, which consists of an upfront payment and additional payments contingent on achieving specific clinical development milestones [3] - Lilly will account for this transaction in accordance with Generally Accepted Accounting Principles (GAAP) once the acquisition is finalized [4] Technological Advancements - Orna's lead program, ORN-252, is a clinical trial-ready CAR-T therapy targeting CD19, designed to treat B cell-driven autoimmune diseases, with the potential for more durable therapeutic protein expression compared to existing RNA or cell therapy platforms [2][3] - The combination of Orna's circular RNA technology and its lipid nanoparticle delivery system is expected to unlock new in vivo CAR-T therapies for a range of autoimmune diseases [3][6][7]

CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims regarding the Company’s research programs, clinical progress, and operations.The company said, ” CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company’s scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed’s research is focu ...

Core Insights - Novo Nordisk and Aspect Biosystems are entering a new phase of their partnership to develop advanced cellular medicines for diabetes, building on their existing collaboration since 2023 [1][2] Company Developments - Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk, leading development, manufacturing, and commercialization [3] - Novo Nordisk will make an additional equity investment in Aspect and provide research funding for the development of potentially curative therapies, with eligibility for royalties and milestone payments on future product sales [4] Strategic Integration - The partnership involves integrating select Novo Nordisk cell therapy research, development, and manufacturing capabilities from the US and Denmark into Aspect's platform in Canada, enhancing Aspect's capabilities and access to skilled talent [5][8] - Aspect aims to develop a new class of cellular medicines, including an islet replacement therapy for type 1 diabetes, designed to restore blood glucose control without chronic immune suppression [6] Company Backgrounds - Aspect Biosystems is a biotechnology company focused on developing cellular medicines to replace or restore biological functions for serious diseases, utilizing a full-stack tissue therapeutic platform [7] - Novo Nordisk, founded in 1923, is a global healthcare leader committed to combating chronic diseases, particularly diabetes, employing approximately 78,500 people across 80 countries [9]